Risk of osteoporotic fractures for Central Federal District residents: Results from the epidemiologic study

Introduction. For successful planning and implementation of measures for the prevention and treatment of osteoporosis (OP), data on the prevalence of clinical risk factors (FR) of the disease and the frequency of high risk of osteoporotic fractures (OP-fractures) in a particular population are needed.

Aim. To establish the prevalence of high risk of OP-fractures using the FRAX® instrument based on an assessment of the incidence of clinical RF for OP among the urban population of the Central Federal Region of the Russian Federation.

Materials and methods. The study included 7,320 residents (5,613 women and 1,707 men) aged 50 years and older from 9 cities with a population of more than 100,000 people. A questionnaire was conducted on the main RF of OP, daily calcium intake and physical activity during the month preceding the survey were assessed.

Results. The most common clinical RF of OP were the presence of a low-energy fracture after the age of 40 (29.3%), the causes of secondary OP (23.2%), and smoking (10.8%). 39.9% of the surveyed individuals had three or more RF, including 41.4% of women and 35.1% of men (p < 0.05). The daily calcium intake ≥ 1000 mg was detected only in 9% of women and 5% of men. Low physical activity was recorded in 24.9% of the surveyed individuals, while significantly less among men (20.4%) than among women (26.3%), p < 0.05. 32% of women and 3.6% of men had a high 10-year probability of major OP fractures (p < 0.05).

Conclusions. The most common RF of OP were insufficient intake of dietary calcium, low physical activity, previous low-energy fracture after the age of 40, smoking and the causes of secondary OP in residents aged ≥ 50 years. About 1/3 of women and 3.6% of men in this region had a risk of major OP-fractures according to the FRAX® above the threshold of therapeutic intervention and they need to be prescribed a course of anti-osteoporotic therapy.

1. Lesnyak OM, Baranova IA, Belova KYu, Gladkova EN, Evstigneeva LP, Ershova OB et al. Osteoporosis in Russian Federation: Epidemiology, Socio-Medical and Economical Aspects (Review). Traumatology and Orthopedics of Russia. 2018;24(1):155–168. (In Russ.) https://doi.org/10.21823/2311-2905-2018-24-1-155-168.

2. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397. https://doi.org/10.1007/s00198-007-0543-5.

3. Tan THA, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey E, Schini M. Assessment of fracture risk with FRAX and FRAXplus. Gac Med Mex. 2024;160(4):363–373. https://doi.org/10.24875/GMM.24000107.

4. Nikitinskaya OA, Toropcova NV. Social Program “Osteoscreening Russia” at Work. Farmateka. 2012;239(6):90–93. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/8412.

5. Drapkina OM, Koncevaya AV, Kalinina AM, Avdeev SN, Agal’cov MV, Alekseeva LI et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention (Russian Federation). 2024;23(3):113–418 (In Russ.) https://doi.org/10.15829/17288800-2024-3996.

6. McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E et al. Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe. Arch Osteoporos. 2022;17(1):20. https://doi.org/10.1007/s11657-021-01048-8.

7. Skripnikova IA, Gur’ev AV, Shalnova SA, Deev AD, Myagkova MA, Indukaeva EV et al. The prevalence of clinical factors used for risk assessment of osteoporotic fractures. Profilakticheskaya Meditsina. 2016;19(5):32–40. (In Russ.) https://doi.org/10.17116/profmed201619532-40.

8. Насонов ЕЛ (ред.). Ревматология: клинические рекомендации. 2-е изд. испр. и доп. М.: ГЭОТАР-Медиа; 2010. 752 с.

9. Taylor-Williams O, Keen H, Preen DB, Nossent J, Inderjeeth CA. First fracture in rheumatoid arthritis: Analysis by fracture site, gender, age, and comorbidities. Osteoporos Int. 2025;36(1):113–121. https://doi.org/10.1007/s00198-024-07311-1.

10. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocortidoid usage in the United States: a general population perspective. Arthr Care Res. 2013;65(2):294–298. https://doi.org/10.1002/acr.2179624.

11. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011;50(11):1982–1990. https://doi.org/10.1093/rheumatology/ker017.

12. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000. https://doi.org/10.1359/jbmr.2000.15.6.993.

13. Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, Burden AM. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: A population-based casecontrol study. Arch Osteoporos. 2018;13(1):30. https://doi.org/10.1007/s11657-018-0424-x.

14. Soen S, Kaku M, Okubo N, Onishi Y, Saito K, Kobayashi M. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan. J Bone Miner Metab. 2022;40(4):636–647. https://doi.org/10.1007/s00774-022-01325-7.

15. Rizzoli R, Abraham C, Brandi ML. Nutrition and bone health: turning knowledge and beliefs into healthy behaviour. Curr Med Res Opin. 2014;30(1):131–141. https://doi.org/10.1185/03007995.2013.847410.

16. Estok PJ, Sedlak CA, Doheny MO, Hall R. Structural model for osteoporosis preventing behavior in postmenopausal women. Nurs Res. 2007;56(3):148–158. https://doi.org/10.1097/01.NNR.0000270031.64810.0c.

17. Belaya ZE, Belova KYu, Biryukova EV, Dedov II, Dzeranova LK, Drapkina OM et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4–47. (In Russ.) https://doi.org/10.14341/osteo12930.

18. Shafieva IA, Bulgakova SV, Kurmaev DP, Treneva EV. Evaluation of the Effectiveness of Zoledronic Acid Preparations for Parenteral Use. Effective Pharmacotherapy. 2024;20(37):6–12. (In Russ.) https://doi.org/10.33978/2307-3586-2024-20-37-6-12.

19. Shafieva IA, Bulgakova SV, Shafieva AV. Evaluation of the tolerability of zoledronic acid preparations for parenteral administration. Meditsinskiy Sovet. 2022;16(11):96–101. (In Russ.) https://doi.org/10.21518/2079-701X2022-16-11-96-101.

20. Toroptsova NV, Efremova AO, Korotkova TA, Dobrovolskaya OV, Demin NV, Feklistov AY et al. Treatment of osteoporosis in clinical practice: first experience with the Russian generic drug of zoledronic acid. Sovremennaya Revmatologiya. 2022;16(2):56–61. (In Russ.) https://doi.org/10.14412/19967012-2022-2-56-61.

21. Shalina MA, Yarmolinskaya MI. Impact assessment of ibandronic acid use in patients with postmenopausal osteoporosis. Russian Bulletin of ObstetricianGynecologist. 2023;23(3):92–99. (In Russ.) https://doi.org/10.17116/rosakush20232303192.

22. Mazurov VI, Lesnyak OM, Belova KIu, Ershova OB, Zotkin EG, Marchenkova LA et al. Algorithm for selection of drug for osteoporosis treatment in primary care and in organization of provision with medicinal products of citizens eligible for state social assistance. Review of the literature and position of Russian Association on Osteoporosis Expert Council. Profilakticheskaya Meditsina. 2019;22(1):57–65. (In Russ.) https://doi.org/10.17116/profmed20192201157.